Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Interest Expenses (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Interest Expenses data on record, last reported at $3.6 million in Q4 2025.

  • For Q4 2025, Interest Expenses rose 0.53% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $14.4 million, up 0.55%, while the annual FY2025 figure was $14.4 million, 0.55% up from the prior year.
  • Interest Expenses reached $3.6 million in Q4 2025 per MIRM's latest filing, roughly flat from $3.6 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $5.7 million in Q3 2021 and bottomed at $3.4 million in Q1 2021.
  • Average Interest Expenses over 5 years is $3.9 million, with a median of $3.6 million recorded in 2025.
  • Peak YoY movement for Interest Expenses: surged 1024.18% in 2021, then fell 29.93% in 2022.
  • A 5-year view of Interest Expenses shows it stood at $3.8 million in 2021, then grew by 15.75% to $4.4 million in 2022, then fell by 18.26% to $3.6 million in 2023, then increased by 0.45% to $3.6 million in 2024, then grew by 0.53% to $3.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $3.6 million in Q4 2025, $3.6 million in Q3 2025, and $3.6 million in Q2 2025.